The Kuwaiti government has approved the use of Lianhua Qingwen, a traditional Chinese herbal medicine for the treatment of Covid-19 in the first international support of its kind. This was disclosed by drug manufacturer Shijiazhuang Yiling Pharmaceutical.
This is the first time that Lianhua Qingwen has been granted permission in a country other than China to treat mild and moderate symptoms caused by the Covid-19 case.
Also Read: Legitimate, WHO Prepares Clinical Trials of African Herbs as Covid-19 Medicine
“Lianhua Qingwen, a patented traditional Chinese medicine that is widely used in China to treat patients suffering from Covid-19, has been certified by the Kuwaiti Pharmaceutical and Herbal Medicine Registration and Control Administration for the treatment of symptoms caused by Covid-19,” Yiling Pharma said.
“The drug will be registered as a drug that can be used to treat symptoms including fever, cough, muscle pain, congestion, colds and headaches caused by viral diseases including seasonal influenza, influenza, Influenza A virus subtype H1N1, Severe Acute Respiratory. Syndrome and mild and moderate cases of Covid-19, “he continued, as reported by GMP News on Monday (21/09/2020).
Lianhua Qingwen, known for its anti-viral and anti-inflammatory properties, is licensed for sale in several overseas markets including Brazil, Indonesia, Canada, Romania, Thailand and Singapore.
This herbal remedy consists of a number of plants which are well known for their properties including Lonicera japonica and Fructus forsythia. Another ingredient, Pogostemon cablin, is used to stop diarrhea and to treat viral infections of the digestive tract.
Content Syndication Partners: SINDOnews
– .
